Current roles and realities of noninvasive assessment of osteoporosis

Current Opinion in Endocrinology and Diabetes

Volumn 11, Issue 6, 2004, Pages 330-337

  Burke, M Susan ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU HOSPITAL   (United States)

^c Lankenau Internal Medicine Clinical Care Center   (United States)

Author keywords

Biochemical markers; Bone mineral density; Bone quality; Bone remodeling (turnover); Fracture

Indexed keywords

BIOCHEMICAL MARKER; PLACEBO; RALOXIFENE;

BONE DENSITOMETRY; BONE REMODELING; BONE TURNOVER; CLINICAL ASSESSMENT; FRACTURE; HUMAN; MONITORING; NON INVASIVE PROCEDURE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 33750297578     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000145446.27182.78     Document Type: Review

References (24)

1. Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:378-381.
2. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
3. US Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002, 137:526-528.
4. Lieb ES, Lewiecki EM, Binkley N, et al.: Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004, 7:1-5. An excellent concise summary of the present state of BMD testing. It also includes guidelines for testing of men, children, and premenopausal women.
5. Hui SL, Slemenda CW, Johnston CC Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988, 81:1804-1809.
6. Lindsay R, Silverman S, Cooper R, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320-323.
7. Schuit SCE, van der Klift M, Weel AEAM, et al.: Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004, 34:195-202. The authors found that the correlation between BMD and fracture risk was even less in men. These results highlight the need for better risk assessment tools to predict fracture risk.
8. Siris ES, Chen Y-T, Abbott TA, et al.: Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004, 164:1108-1112. This study complements [7], this time showing the increased risk for fracture in osteopenic patients.
9. Miller PD, Barlas S, Brenneman SK, et al.: An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004, 164:1113-1120. This paper offers a useful approach to identifying osteopenic patients at increased fracture risk.
10. Wasnich RD, Miller PD: Antifracture efficacy of agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231-236.
11. Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 2002, 112:281-289.
12. Delmas PD, Seeman E: Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004, 34:599-604.
13. Watts NB, Cooper C, Lindsay R, et al.: Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densit 2004, 7:255-261.
14. Garnero P, Hausherr E, Chapuy MC, et al.: Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996, 11:1531-1538.
15. Riis SBJ, Hansen AM, Jensen K, et al.: Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15 year follow-up study. Bone 1996, 19:9-12.
16. Riggs BL, Melton LJ, O'Fallon WM: Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18:197S-201S.
17. Dulipsingh L, De Souza MJ, Ikram Z, et al.: Clinical utility of urinary markers of bone turnover in response to antiresorptive therapies. Endocrinologist 2003, 13:293-299.
18. Yates J, Barrett-Connor E, Barlas S, et al.: Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004, 103:440-446. It is already known that estrogen cessation causes a decrease in BMD; this article stresses that it also results in a higher risk for hip fractures.
19. Epstein S, Inzerillo AM, Caminis J, et al.: Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003, 18:2083-2094. This is a comprehensive review stressing mechanisms of bone loss and resultant increase in fracture risk seen in certain diseases.
20. Johnell O, Oden A, De Laet C, et al.: Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002, 13:523-526.
21. Miller PD, Baran DT, Bilezikian JP, et al.: Practical clinical application of biochemical markers of bone turnover. J Clin Densitom 1999, 2:323-342.
22. Sarkar S, Reginster J-Y, Crans GG, et al.: Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004, 19:394-401. is article adds to the growing evidence that BMD is sometimes a poor predictor fracture risk.
23. Clowes JA, Peel NFA, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:1117-1123. Urine markers do not appear to be any better than nurse monitoring in improving compliance with therapy.
24. Seibel MK, Naganathan V, Barton I, et al.: Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Min Res 2004, 19:323-329. It would be nice to identify reasonable uses for biochemical marker testing. Unfortunately, the results of this study offer no benefit to determining the turnover state of the patient to guide the choice of therapy.